NCT07366801 Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
| NCT ID | NCT07366801 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
| Condition | Acute Myeloid Leukemia, Relapsed |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-09-03 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 64 participants in total. It began in 2025-09-03 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of GVHD prevention. Modern graft engineering technologies make it possible to create a graft with a balanced cell composition, reducing the risk of adverse events, in particular, severe forms of acute and chronic GVHD, while preserving the immunological function of the graft. In the proposed concept, enrichment of the T graft with regulatory cells will reduce the risk of GVHD and preserve a sufficient number of T lymphocytes in the graft for the formation of protective anti-infective immunity in the early stages after HSCT. The combination of partial T depletion and pharmacological immunosuppression minimized in volume and duration will combine the advantages of T depletion (early engraftment, low risk of GVHD, low risk of organ complications) and pharmacological prophylaxis (restoration of anti-infective immunity).
Eligibility Criteria
Inclusion Criteria: 1. Informed consent signed by the patient (age 14 to 25 years) and/or his/her legal representative (age 0 to 18 years). 2. The patient has an indication for allogeneic hematopoietic stem cell transplantation (HSCT) established in accordance with the current regulatory framework 3. Planned HSCT from a haploidentical donor 4. The Karnofsky or Lansky score is more than 70% 5. Life expectancy of at least 8 weeks 6. Heart function: ejection fraction of at least 40% 7. Consent to continue follow-up for 3 years Exclusion Criteria: 1. Acute viral hepatitis or acute HIV infection 2. Hypoxemia with SaO2 \<90% 3. Bilirubin \>3 normal 4. Creatinine \>3 norms 5. Pregnancy and lactation 6. Life-threatening infection 7. Severe (\>?) pathology of the central nervous system (epilepsy, dementia, organic damage to the central nervous system) 8. Karnofsky score or Lansky score \<70%
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07366801 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 25 Years, studying Acute Myeloid Leukemia, Relapsed. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07366801 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07366801 currently recruiting?
Yes, NCT07366801 is actively recruiting participants. Contact the research team at mmaschan@yandex.ru for enrollment information.
Where is the NCT07366801 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT07366801 clinical trial?
NCT07366801 is sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology. The trial plans to enroll 64 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.